
In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.
The pulmonology and oncology expert panel returns for another discussion on lung cancer treatment challenges presented by the pandemic—and how the field can recover.




